SUNNYVALE, California,
April 17, 2018 /PRNewswire/ --
Unique Hologram
Technology Will Showcase the Benefits
Accuray Radiotherapy Systems and Software Solutions Provide
to Patients
Accuray Incorporated (Nasdaq: ARAY) announced today it will be
showcasing the benefits of its radiotherapy systems and software
solutions at the 37th annual European Society for Radiotherapy and
Oncology (ESTRO) meeting in Barcelona,
Spain. The meeting, to be held April
20-24, 2018, will attract more than 3,000 radiation oncology
professionals who will gather to gain information and insights on
the latest developments in radiation therapy. Accuray will be in
attendance at booth #1700, sharing information on new treatment
approaches and providing opportunities for conversations about how
the company's innovative CyberKnife® and
Radixact® Systems, and advanced software solutions, can
help improve the radiation therapy treatment experience for
clinicians and their patients.
"This year, Accuray has chosen a theme which is anchored in our
company culture and conveys our new corporate positioning:
'Innovating Patient-First Cancer Treatment.' This is not just a
tagline. It is who we are, what we do and what makes us different.
As the fight against cancer grows more complex, we will continually
introduce new thinking and fresh tools to drive patient outcomes to
entirely new levels," said Lionel Hadjadjeba, M.D., Senior Vice
President, and Chief Commercial Officer at Accuray.
Special Events: Accuray Booth #1700
Accuray is building on its history of innovation with a new
approach for demonstrating product features and benefits, and a new
award recognizing customer advances achieved with its products.
April 21, 2018 at 9:30 a.m.: Unveiling of hologram technology,
"viRTual - Where Art Meets Science"
April 21, 2018 at 2:10 p.m.: Announcement of first annual ESTRO
Accuray Innovation Awards
Accuray ESTRO37 Highlights:
Advances in Software Solutions
- VOLO™ Technology for the CyberKnife System: a state-of-the art
optimizer that simplifies the process of creating treatment plans,
improves plan quality and enables more efficient exploration of the
tradeoffs between treatment time and plan quality. Preliminary data
indicates that the VOLO technology will provide a significant
reduction in optimization time, as well as a reduction in overall
treatment time. Technology under development for the
CyberKnife System - not available for
sale.
- CTrue™ IR (Iterative Reconstruction) for the Radixact System:
this new image guidance software improves soft-tissue contrast and
reduces noise, enhancing image quality, while maintaining the same
low imaging dose and fast reconstruction time as earlier versions
of the software. Patient workflows are also more efficient,
facilitating the delivery of precise treatments more quickly, for
more patients.
Radiation Oncology Experts Share First-Hand Experience with
Accuray Technologies
ESTRO attendees are invited to take part in multiple educational
opportunities. Over the course of the meeting, a symposium and
numerous Accuray Exchange in Radiation Oncology (AERO™) sessions
will provide information on a range of subjects designed to advance
clinical practice and enhance patient outcomes.
Click here for more information about the daily sessions and
here for details on the symposium.
- Accuray Symposium: Saturday, April 21 from 13:15 pm to 14:15 pm in Room 116
- Prof. Veronica Dell'Acqua,
European Institute of Oncology (IEO), Milan (Italy)
will discuss how to improve the quality of breast cancer treatments
with the TomoTherapy® System
- Dr. Maaike Milder, Erasmus MC,
Rotterdam (Netherlands) will share her experience using
the CyberKnife® platform to minimize margins and
maximize precision and accuracy
- AERO Sessions: April 21st -
April
23rd
Interactive sessions will be held daily throughout the meeting
at the Accuray booth. Attendees will have the opportunity to engage
in discussions with industry experts on a variety of topics
including: the feasibility of real-time motion management on the
Radixact® System, tips and tricks to treat
localized prostate cancer with the CyberKnife System, tips
and tricks for TomoDirect™ breast treatment planning,
re-treatment with PreciseRTX™ Re-treatment option, and adaptive
radiation therapy using PreciseART™ Adaptive Radiation Therapy
software.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit http://www.accuray.com or follow us on Facebook, LinkedIn,
Twitter and YouTube .
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and outcomes, the
availability and effectiveness of new product enhancements and
releases, and Accuray's leadership position in radiation oncology
innovation and technologies. These forward-looking statements
involve risks and uncertainties. If any of these risks or
uncertainties materialize, or if any of the company's assumptions
prove incorrect, actual results could differ materially from the
results expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, the
company's ability to achieve widespread market acceptance of its
products, including new product offerings, the company's ability to
develop new products or enhance existing products to meet
customers' needs, delays in the development or release of new
offerings and such other risks identified under the heading "Risk
Factors" in the company's annual report on Form 10-K, filed with
the Securities and Exchange Commission (the "SEC") on August 25, 2017, the company's quarterly report
on Form 10-Q, filed with the SEC on February
5, 2018 and as updated periodically with the company's other
filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact:
Sancie Nakarat
+33-6-81-36-84-34
snakarat@accuray.com
SOURCE Accuray Incorporated